首页> 美国卫生研究院文献>BMC Cancer >Phase I trial of split-dose induction docetaxel cisplatin and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
【2h】

Phase I trial of split-dose induction docetaxel cisplatin and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)

机译:局部晚期口腔和口咽鳞状细胞癌(TISOC-1)患者的分剂量诱导多西他赛顺铂和5-氟尿嘧啶(TPF)化疗+根治性手术联合术后放疗的I期试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundInduction chemotherapy (ICT) with docetaxel, cisplatin and fluorouracil (TPF) followed by radiotherapy is an effective treatment option for unresectable locally advanced head and neck cancer. This phase I study was designed to investigate the safety and tolerability of a split-dose TPF ICT regimen prior to surgery for locally advanced resectable oral and oropharyngeal cancer.
机译:背景采用多西他赛,顺铂和氟尿嘧啶(TPF)的诱导化疗(ICT)继之以放射疗法,是无法切除的局部晚期头颈癌的有效治疗选择。 I期研究旨在研究局部晚期可切除口腔和口咽癌手术前分剂量TPF ICT方案的安全性和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号